Pharma firms turn attention to hearing loss

Hearing loss affects 36 million Americans to some degree, often leaving them feeling isolated, but it has received little attention from the pharmaceutical industry—until now. Small firms have brought a handful of potential therapies to the development pipeline, and pharmaceutical heavyweights are taking notice, according to an article in Chemical & Engineering News (C&EN), the weekly magazine of the American Chemical Society.

The story states that the most common cause of hearing loss is loud noise, either from a single event like the bang of a firecracker or from chronic exposure, say daily listening to a cranked-up iPod. Although severe hearing loss can be treated with a hearing aid or cochlear implants, options are scarce for those suffering from milder damage. But there is growing interest to fill the void and to even develop preventative treatments. Several drug candidates have already advanced through early clinical testing in patients.

Lisa M. Jarvis, a senior editor at C&EN, notes that potential treatments generally focus on two areas: the inner ear, where sound is first perceived, and the central nervous system (including the brain), where sound is processed. Researchers are using small molecules and gene therapy approaches to target different components, from re-growing the ear's hair cells to controlling how nerve cells involved in hearing work. Small companies firing up the field such as Audion Therapeutics have shown enough success that deeper-pocketed firms Eli Lilly & Co., Novartis and Roche are backing them up.

More information: "Sound Science" cen.acs.org/articles/92/i14/Sound-Science.html

add to favorites email to friend print save as pdf

Related Stories

Implanted hearing device approved

Mar 20, 2014

(HealthDay)—The first implantable device for adults with a severe or profound form of a condition called "sensorineural hearing loss" has been approved by the U.S. Food and Drug Administration.

Imbalanced hearing is more than a mild disability

Mar 12, 2014

Researchers at Washington University School of Medicine in St. Louis have received a five-year, $3 million grant from the National Institutes of Health (NIH) to study the effects of asymmetric hearing loss ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

15 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

15 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

16 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

16 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments